Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during intervention
Awards & highlights
Study Summary
This trial will test whether changes in liver glycogen content affects hypoglycemic responses in people without type 1 diabetes.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ during intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during intervention
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Epinephrine
Glucagon
Glucose infusion rate
Secondary outcome measures
Glucose
Peripheral glucose uptake
Side effects data
From 2015 Phase 4 trial • 15 Patients • NCT013803667%
Hospitalization for Escherichia coli Infection
7%
Hospitalization for Gram-positive Cocci
7%
Hospitalization for positive line infection
7%
Pancreatitis
7%
Hospitalization for abdominal pain (pre-treatment)
7%
Hospitalization for Flu like Symptoms
100%
80%
60%
40%
20%
0%
Study treatment Arm
Patients Consented to be Given rHGH
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: FastingExperimental Treatment1 Intervention
Subjects will remain fasted prior to insulin-induced hypoglycemia.
Group II: FeedingActive Control1 Intervention
Subjects will eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
Find a Location
Who is running the clinical trial?
University of CincinnatiLead Sponsor
427 Previous Clinical Trials
634,350 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger